ReviewFrontiers in microbiology2026
Complex interactions of gut-derived short-chain fatty acids in hyperuricemia and gout pathophysiology.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Saponins Derived from Chinese Medicinal Materials in Hyperuricemia and Gout: Therapeutic Mechanisms and Emerging Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Mechanisms of Gut Microbiota-Derived Metabolites in Treating Hyperuricemia: Natural Products as Interventions.Molecules (Basel, Switzerland) · 2026Review
- Hydroxypropyl starch enhances gut health in geese.Poultry science · 2026Article
- From uric acid to tophi: multistage molecular and cellular mechanisms of tophi formation.Frontiers in immunology · 2026Review
- The role of the gut microbiota-uric acid metabolism axis in high-altitude hyperuricemia: dysregulation mechanisms, pathway associations and therapeutic perspectives.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia is a common metabolic disorder associated with gout, kidney injury, cardiovascular disease, and chronic low-grade inflammation. Increasing evidence indicates that abnormalities in intestinal uric acid handling and gut microbial metabolism contribute substantially to systemic urate imbalance, particularly when renal excretion is impaired. Among microbiota-derived metabolites, short-chain fatty acids (SCFAs) have emerged as key regulators linking gut microbial ecology with uric acid metabolism through coordinated effects on epithelial barrier integrity, inflammatory signaling, and urate transport. Growing interest in prebiotics and probiotics has further highlighted the therapeutic potential of targeting SCFAs production as a complementary strategy to traditional urate-lowering drugs. Given that hyperuricemia is the primary pathogenic precursor to gout, this review also examines the role of SCFAs in modulating gout-associated inflammation. This review integrates current findings on the microbiota-SCFA-urate axis and outlines how SCFA-centered gut modulation may provide a viable framework for managing hyperuricemia and gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.